Eli Lilly stock swings after FDA liver failure report for GLP-1 drug
Eli Lilly (LLY) stock initially sold off on Monday morning, May 4, after the FDA disclosed a liver failure report tied to the company’s new oral obesity drug Foundayo, but shares recovered as analysts argued the reaction may have been overdone. The episode shifted investor attention toward the …
Eli Lilly (LLY) stock initially sold off on Monday morning, May 4, after the FDA disclosed a liver failure report tied to the company’s new oral obesity drug Foundayo, but shares recovered as analysts argued the reaction may have been overdone. The episode shifted investor attention toward the …
Eli Lilly (LLY) stock initially sold off on Monday morning, May 4, after the FDA disclosed a liver failure report tied to the company’s new oral obesity drug Foundayo, but shares recovered as analysts argued the reaction may have been overdone. The episode shifted investor attention toward the …
The full story continues on The Street.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.